OBJECTIVES: This study sought to evaluate whether the therapeutic effects of an anti-inflammatory drug such as minocycline could be monitored by serial ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI in experimental stroke. METHODS: Mice received a three-dose minocycline treatment (n = 12) or vehicle (n = 12) after permanent middle cerebral artery occlusion. USPIOs were administered 5 h post-surgery. MRI was performed before, 24 h and 48 h post-USPIO administration. MRI endpoints were the extent of signal abnormalities on R2 maps (=1/T2) and quantitative R2 changes over time (∆R2). Post-mortem brains were prepared either for immunohistology (n = 16) or for iron dosage (n = 8). RESULTS: As expected, treatment with minocycline significantly reduced infarct size, blood-brain barrier permeability and F4/80 immunostaining for microglia/macrophages. Areas of R2 maps > 35 ms(-1) also appeared significantly decreased in minocycline-treated mice (ANOVA for repeated measures, P = 0.017). There was a fair correlation between these areas and the amount of iron in the brain (R(2) = 0.69, P = 0.010), but no significant difference in ∆R2 was found between the two groups. CONCLUSIONS: This study showed that the extent of signal abnormalities on R2 maps can be used as a surrogate marker to detect minocycline effects in a murine experimental model of stroke.
OBJECTIVES: This study sought to evaluate whether the therapeutic effects of an anti-inflammatory drug such as minocycline could be monitored by serial ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI in experimental stroke. METHODS:Mice received a three-dose minocycline treatment (n = 12) or vehicle (n = 12) after permanent middle cerebral artery occlusion. USPIOs were administered 5 h post-surgery. MRI was performed before, 24 h and 48 h post-USPIO administration. MRI endpoints were the extent of signal abnormalities on R2 maps (=1/T2) and quantitative R2 changes over time (∆R2). Post-mortem brains were prepared either for immunohistology (n = 16) or for iron dosage (n = 8). RESULTS: As expected, treatment with minocycline significantly reduced infarct size, blood-brain barrier permeability and F4/80 immunostaining for microglia/macrophages. Areas of R2 maps > 35 ms(-1) also appeared significantly decreased in minocycline-treated mice (ANOVA for repeated measures, P = 0.017). There was a fair correlation between these areas and the amount of iron in the brain (R(2) = 0.69, P = 0.010), but no significant difference in ∆R2 was found between the two groups. CONCLUSIONS: This study showed that the extent of signal abnormalities on R2 maps can be used as a surrogate marker to detect minocycline effects in a murine experimental model of stroke.
Authors: Susan C Fagan; Jennifer L Waller; Fenwick T Nichols; David J Edwards; L Creed Pettigrew; Wayne M Clark; Christiana E Hall; Jeffrey A Switzer; Adviye Ergul; David C Hess Journal: Stroke Date: 2010-08-12 Impact factor: 7.914
Authors: Yoshihiro Murata; Anna Rosell; Robert H Scannevin; Kenneth J Rhodes; Xiaoying Wang; Eng H Lo Journal: Stroke Date: 2008-10-16 Impact factor: 7.914
Authors: J-C Brisset; V Desestret; S Marcellino; E Devillard; F Chauveau; F Lagarde; S Nataf; N Nighoghossian; Y Berthezene; M Wiart Journal: Eur Radiol Date: 2009-08-25 Impact factor: 5.315
Authors: M Marinescu; M Langer; A Durand; C Olivier; A Chabrol; H Rositi; F Chauveau; T H Cho; N Nighoghossian; Y Berthezène; F Peyrin; M Wiart Journal: Mol Imaging Biol Date: 2013-10 Impact factor: 3.488
Authors: Shirjel R Alam; Colin Stirrat; Jennifer Richards; Saeed Mirsadraee; Scott I K Semple; George Tse; Peter Henriksen; David E Newby Journal: J Cardiovasc Magn Reson Date: 2015-09-18 Impact factor: 5.364